CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.4613
39.3136
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
CSPC Innovation Pharmaceutical Co Ltd
Cost of Revenue
CSPC Innovation Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Cost of Revenue
-¥1.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cost of Revenue
-¥1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Cost of Revenue
-¥5.9B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-24%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cost of Revenue
-¥3.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-11%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cost of Revenue
-¥28.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cost of Revenue
-¥242.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CSPC Innovation Pharmaceutical Co Ltd
Glance View
CSPC Innovation Pharmaceutical Co., Ltd., founded in 1997, has emerged as a prominent player in China's pharmaceutical landscape, with a mission to create innovative healthcare solutions. As a subsidiary of CSPC Pharmaceutical Group, the company is committed to research and development, focusing on both generic and specialty pharmaceuticals. By leveraging advanced technologies and a robust pipeline of drug candidates, CSPC Innovation has positioned itself as a pioneer in addressing critical healthcare needs in areas such as oncology, cardiovascular diseases, and infectious diseases. Investors can take note of its impressive track record in developing new drugs, attracting substantial investments through strategic partnerships and collaborations, which bolster its ability to compete in a rapidly evolving market. As the global demand for new therapies escalates, CSPC Innovation is not only positioned for growth within the domestic market but also aims for international expansion. The company's emphasis on quality and compliance with international pharmaceutical standards enhances its credibility and facilitates entry into foreign markets. With a strong balance sheet and a commitment to innovation, CSPC Innovation is poised to capture opportunities in the vast healthcare sector, making it an appealing option for investors looking to participate in the burgeoning global pharmaceutical industry. The synthesis of cutting-edge research, a dedicated workforce, and a growing portfolio of patented drugs contributes to its potential for sustainable growth, ultimately enhancing shareholder value.
See Also
What is CSPC Innovation Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-1.2B
CNY
Based on the financial report for Sep 30, 2024, CSPC Innovation Pharmaceutical Co Ltd's Cost of Revenue amounts to -1.2B CNY.
What is CSPC Innovation Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-13%
Over the last year, the Cost of Revenue growth was 29%. The average annual Cost of Revenue growth rates for CSPC Innovation Pharmaceutical Co Ltd have been -22% over the past three years , -13% over the past five years .
You don't have any saved screeners yet
